World & Nation

Former drug company executives to be sentenced in opioid bribery case

Insys Therapeutics founder John Kapoor
Insys Therapeutics founder John Kapoor leaves federal court in Boston last year.
(Steven Senne / Associated Press)

The founder and former top employees of a pharmaceutical company are facing a reckoning for their role in a bribery scheme that prosecutors say boosted sales of a powerful, highly addictive painkiller and helped fuel the national opioid epidemic.

Starting Monday, seven people who worked for Insys Therapeutics will appear in Boston to be sentenced by a federal judge.

The case against company founder John Kapoor and his associates was considered the first that sought to hold an opioid maker and its executives criminally liable for the drug crisis that has claimed nearly 400,000 lives over two decades.

At least two other companies, a drug distributor in New York and another in Ohio, have since been hit with criminal charges. But prominent industry names — specifically OxyContin maker Purdue Pharma and the Sackler family that owns it — have faced only lawsuits that carry no threat of prison time.


Prosecutors say officials at Arizona-based Insys Therapeutics paid millions of dollars in bribes to doctors across the country so they would overprescribe Subsys, a fentanyl-based oral spray meant to ease intense pain suffered by cancer patients.

Insys Therapeutics also deployed other questionable marketing tactics, according to prosecutors. One sales executive, who prosecutors said used to be an exotic dancer, gave a physician a lap dance at a club. And the company misled insurers to get payments for the drug, which could cost as much as $19,000 a month.

After a lengthy trial, Kapoor and four others were convicted last year of racketeering conspiracy. Two other defendants pleaded guilty.

Shortly after, the company reached a $225-million settlement with the U.S. Department of Justice to end its criminal and civil probes.


Insys Therapeutics has since filed for bankruptcy protection, and it’s not clear whether the company will fully pay what’s owed. The company has been approved to sell off Subsys and its other drugs for about $30 million, but it maintains that its assets, all told, are worth only $175 million.

U.S. Atty. Andrew Lelling in Massachusetts, whose office is prosecuting the case, said Insys Therapeutics has already paid $5 million toward the $195-million civil settlement with the government. A $2-million criminal fine and $28-million forfeiture haven’t been paid.

Though the defendants can face up to 20 years for the charges, prosecutors are seeking sentences for the associates of five to 11 years, and 15 years for Kapoor, arguing that the former billionaire was the “fulcrum” of the scheme, according to recent court filings.

Kapoor’s lawyers counter their client was portrayed as a “caricature” of a mob boss but is really the “consummate immigrant success story.”

They say in their filings that the India-born exec developed Subsys after seeing his wife suffer and die from breast cancer. They’re seeking no more than a year and a day in prison for Kapoor.

Michael Gurry, an Arizona resident who was a company vice president, will be the first sentenced Monday.

Richard Simon, a California resident who had been the company’s head of sales, will follow on Jan. 21, along with Joseph Rowan of Florida, who was a regional sales director.


Sunrise Lee, a Michigan resident and former regional sales director, will be sentenced Jan. 22 along with Michael Babich, an Arizona resident and former company chief executive.

Kapoor will be sentenced Jan. 23 along with Alec Burlakoff, a North Carolina resident who was the company’s vice president of sales.

Babich and Burlakoff both pleaded guilty and were key witnesses for prosecutors.

Get our Today's Headlines newsletter